We are excited to be included on the new Hugging Science site from @hf.co! Scientific datasets and models deserve a dedicated space. You can find our drug-target interaction dataset on Hugging Face here: huggingface.co/datasets/eve...
EvE Bio
@evebio.bsky.social
EvE Bio is a nonprofit biomed research institute in Durham NC. We're a Focused Research Org on a 5-year mission to create the discipline of "pharmome mapping." What that means: https://evebio.org. Watch here for job & data drop announcements
EvE Bio is partnering with The OpenAI Foundation on their AI for Alzheimer's initiative! Allosteric modulators hold promise as Alzheimer's drugs, but designing them is hard. AI models could help...if they had the right data. That's where we come in. evebio.org/eve-bio-part...
EvE Bio partners with OpenAI Foundation on "AI for Alzheimer's" : EvE Bio
EvE Bio is partnering with the OpenAI Foundation. Can AI help us design drugs for Alzheimer's? Not without the right data. EvE generates it.
evebio.org
We're busy here at EvE Bio generating drug-target interaction data for GPCR, NR, and kinase targets. Meanwhile, we're expanding our compounds and we want your input! Our current library has 1,300 approved small molecule and peptide drugs. The next will include 6 categories: 🧵
New data is live!! With 25 new kinases, we have a total of 420,497 drug-target interaction results! There are multiple ways to access the dataset 🧵
It's the final day of our data release preview -- data will be posted tomorrow! The last five new targets to preview are metabolic and regulatory kinases: YES, FER, FES, PASK1, and CCK2
Day 5 of our kinase preview for our imminent data release: Emerging Oncology Targets We're adding four kinases gaining traction in cancer drug discovery: PVK2, SVK, TBK1, and CGK2.
It's data release week at EvE! Continuing with day 4 of our preview of the 25 kinases we'll release later this week, today's focus is on stress and survival pathways. We're adding four kinases involved in cellular stress responses: MST2, MSK1, DAPK1, and ROS.
For the day 3 preview of EvE's kinase data release, the theme is calcium. We're adding three "calcium decoders" to our dataset: CaMK2a, CaMKK2, and MLK1.
Day 2 preview of EvE's kinase data release: The RSK Family We're adding 5 ribosomal S6 kinases to our dataset: RSK1, RSK2, RSK3, RSK4, and p70S6K. These kinases are key effectors of the MAPK signaling pathway, and are important targets in cancer research.
At EvE, we release data regularly, and our next release is coming up next week! We're adding 25 more kinases to our public drug-target interaction dataset. Over the next 6 days, we'll preview what's coming. Day 1: The PKC Family
We're excited to share several new developments. Our pharmome mapping dataset is now more accessible and integrated than ever, and the use cases we imagined are coming to life! 🧪 evebio.org/pharmome-dat... Here's what's new: 🧵
Putting Pharmome Data in Researchers' Hands : EvE Bio
We've been busy at EvE Bio these last two years establishing the largest available pharmome mapping dataset. Now it’s making its way into the world to drive real discoveries.
evebio.org
E11 Bio is excited to unveil PRISM technology for mapping brain wiring with simple light microscopes. Today, brain mapping in humans and other mammals is bottlenecked by accurate neuron tracing. PRISM uses molecular ID codes and AI to help neurons trace themselves. Read more: e11.bio/blog/prism
Each of our bimonthly HTS data releases reveals previously unknown drug/off-target interactions, but some, like this snippet from last week's Release 5, showing that capsaicin is a highly selective agonist for the orphan nuclear receptor, ESRRB, deserves special note. 🧵 1/4 🧪
🧪Excited to learn that EvE Bio's unique pharmome-mapping data has been adopted by yet another biomedical reasoning model, Stanford's Biomni (biomni.stanford.edu). Awareness of and appreciation for our efforts is really snowballing. We're grateful to be of service to the community.
🧪EvE will soon make our 1st announcement re: a potential drug repurposing opportunity open for licensing by orgs resourced to bring such things to the clinic. If your org would like early notice of such opptys, drop us a DM (or email list.signup@evebio.org) w/ name, org name, & business email.
🧪 Thank-you to Abhi Mahajan for his long essay on EvE's efforts to map the pharmome. He did a good job of explaining a pretty arcane topic. "EvE really exemplifies the thesis [that] smart people in biology should do more boring things." 🤠 www.owlposting.com/p/mapping-th...
Mapping the off-target effects of every FDA-approved drug in existence (EvE Bio)
6.2k words, 29 minutes reading time
owlposting.com
🧪 New toy! It's a robotic -20C freezer that can store 17,000 sample tubes, and upon command can spit out a rack containing just the tubes you've requested, in whatever pattern you want them. Everything is barcoded so the right sample always ends up in the right place. Or that's what they tell me.
🧪 Exciting to see EvE Bio's ever-expanding pharmome mapping dataset (data.evebio.org) cited as a source of training/test data for @futurehousesf.bsky.social's ether0 LLM, a new scientific reasoning model for chemistry. Preprint: storage.googleapis.com/aviary-publi...
Eve Bio: Pharmome Data
Browse/download data for 1,400 FDA drugs' actions on an ever-growing collection of gene products.
data.evebio.org
🧪 EvE Bio's biggest public data release (#4) yet! 1.4k Rx drugs screened for 24 new potential off-targets including adrenergic, apelin, muscarinic, dopamine, gastrin-releasing, orexin, 5-HT, neuromedin, opioid, prostaglandin, sphingosine, somatostatin & neuromedin receptors. evebio.org/data
🧵 Today, IMPRINT, a pioneering new nonprofit initiative, is announcing $15 million in philanthropic funding to advance our work to decode the body's immune memory and uncover the causes of chronic diseases. #Immunology #Biotech #BiotechResearch
Press Release May 2025 — Imprint FRO
Imprint FRO launches with $15M in funding
imprint.org
Wake up, babe. EvE Bio's data release #4 just dropped. 1.4k Rx drugs, 85 targets & counting: 237,490 combinations screened (mode/target/compound) 8 median agonists per target (potency < 1 uM) 31 median antagonists per target (potency < 1uM) 🧪Browse or DL (for non-commercial use) at evebio.org/data
Come work with us at EvE Bio in Durham, NC! EvE's Assay Dev team is looking for a pharmacology scientist to develop new cell-based screening assays. While this is a temporary position (filling in for a scientist on family leave) it has potential to become permanent. jobs.lever.co/convergentre...
Convergent Research - Temporary Scientist, Receptor Pharmacologist in Cell-Based Assay Development
Durham NC’s EvE Bio is looking for a receptor biochemist/pharmacologist to join its assay development group at the scientist level. This is a temporary position (5 months) that has the potential to tr...
jobs.lever.co
Our data release #3, now live at data.evebio.org, adds 7 new nuclear receptors + 14 new 7TMs to our ever-growing list of human gene products screened against 1.4K FDA-approved drugs to ID off-targets, train AIs, repurpose drugs, and more. Enjoy! 🧪
Work with us! We seek a data scientist in the Research Triangle w/ great R & Shiny experience, comfort making technical decisions, and some scientific bkgd. This is a hybrid position requiring 2d/wk in our Durham office. 🧪https://jobs.lever.co/convergentresearch/ab999aec-2298-438a-bc54-d368b51cc6f4
🧪
EvE Bio@evebio.bsky.social · last yr.EvE Data Release 2 now live! 1.4K drugs screened vs 21 7TMs: ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, DRD1, DRD2, GAL1, GAL2 GHSR, HRH1, HRH3, HRH4, HTR1A, HTR1B, HTR1D, HTR1F, HTR2A, HTR5, HTR6, and PTH1R in ag & antag modes. data.evebio.org For data drop announcements via email sign up at evebio.org
EvE Data Release 2 now live! 1.4K drugs screened vs 21 7TMs: ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, DRD1, DRD2, GAL1, GAL2 GHSR, HRH1, HRH3, HRH4, HTR1A, HTR1B, HTR1D, HTR1F, HTR2A, HTR5, HTR6, and PTH1R in ag & antag modes. data.evebio.org For data drop announcements via email sign up at evebio.org
Eve Bio: Pharmome Data
Browse/download data for 1,400 FDA drugs' actions on an ever-growing collection of gene products. Data Release 1 now live.
data.evebio.org
Thank you Schmidt Initiative For Long Covid for moving the needle on clinical trials in search of therapeutics for LC. Repurposing Evusheld for LC is an interesting long-shot. 🤞 youtu.be/Nihzqamt5xY?...
Are Monoclonal Antibodies a Possible Treatment for Long COVID? (E23) ft Prof Nancy Kilmas
YouTube video by Long Covid The Answers
youtu.be
Farid's hot takes contradict many dogmas in the AI #drugdesign industry: That attaching the workhorse of the wet lab to the #AI cart will make it go; that designing small molecule drugs with AI will work at all; that all of the startups purporting to use AI are actually telling the truth. 🩺🖥️🧪💊
AI in drug discovery is ‘nonsense,’ but call Schrödinger ‘AI’ if you want, says CEO
Ramy Farid of Schrödinger maintains that AI drug discovery won't work unless physics-based calculations are part of the picture.
statnews.com
🧪 E11 Bio is excited to share a major step towards brain mapping at 100x lower cost, making whole-brain connectomics at human & mouse scale feasible (🧠→🔬→💻). Critical for curing brain disorders, building human-like AI systems, and even simulating human brains. Read more: e11.bio/news/roadmap